(Q33932712)

30 July 2017

title

Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes (English)

1 reference

30 July 2017

1 reference

1 reference

Christopher M O'Connor

3

object named as

Christopher M O'Connor

1 reference

30 July 2017

J Michael Gaziano

1

1 reference

30 July 2017

Anthony H Cincotta

2

1 reference

30 July 2017

Michael Ezrokhi

4

1 reference

30 July 2017

Dean Rutty

5

1 reference

30 July 2017

Z J Ma

6

1 reference

30 July 2017

Richard E Scranton

7

1 reference

30 July 2017

language of work or name

English

0 references

publication date

23 March 2010

1 reference

30 July 2017

1 reference

30 July 2017

volume

33

1 reference

30 July 2017

issue

7

1 reference

30 July 2017

page(s)

1503-1508

1 reference

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported

30 July 2017

copyright license

start time

1 September 2021

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Card

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890350

Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890350

A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either Cycloset or placebo

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890350

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890350

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890350

Sympathetic overdrive and cardiovascular risk in the metabolic syndrome

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890350

The involvement of dopamine in the modulation of sleep and waking

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890350

Endothelial inflammation in insulin resistance

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890350

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890350

Standards of medical care in diabetes

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890350

Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890350

Intensive glycemic control in the ACCORD and ADVANCE trials

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890350

Studies of diabetes, thiazolidinediones, and coronary heart disease

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890350

Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890350

Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890350

Increased mortality in Type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890350

Dopaminergic neurotoxin administration to the area of the suprachiasmatic nuclei induces insulin resistance.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890350

Intracerebroventricular administration of bromocriptine ameliorates the insulin-resistant/glucose-intolerant state in hamsters

29 October 2018

1 reference

12 December 2020

The burden of mortality attributable to diabetes: realistic estimates for the year 2000

1 reference

12 December 2020

Cortisol Secretion in Patients With Type 2 Diabetes: Relationship with chronic complications

1 reference

12 December 2020

Role of the sympathetic nervous system in human hypertension

1 reference

12 December 2020

Identifiers

DOI

10.2337/DC09-2009

1 reference

30 July 2017

1 reference

30 July 2017

1 reference